Advertisement

Breast Cancer Research and Treatment

, Volume 124, Issue 3, pp 607–617 | Cite as

Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers

  • Isabella Castellano
  • Elena Allia
  • Valeria Accortanzo
  • Anna Maria Vandone
  • Luigi Chiusa
  • Riccardo Arisio
  • Antonio Durando
  • Michela Donadio
  • Gianni Bussolati
  • Alan S. Coates
  • Giuseppe Viale
  • Anna Sapino
Preclinical study

Abstract

The purpose of this article is to evaluate the prognostic value of androgen receptor (AR) expression in patients with estrogen receptor (ER)-positive breast cancer, treated with endocrine therapy, with or without the addition of chemotherapy. A consecutive series of 953 patients with ER-positive breast cancer, treated between 1998 and 2003, was selected. Repeated immunohistochemistry confirmed the expression of ER in the tumor of 938 patients. AR expression was measured by immunohistochemistry. The Kaplan–Meier method, logrank test and multivariate Cox models were used to explore the impact of AR expression on time to relapse (TTR) and disease specific survival (DSS) in all patients and in subgroups treated with chemo-endocrine therapy or endocrine therapy alone. AR immunoreactivity was assessable in 859 tumors and positive in 609 (70.9%). AR expression was a significant marker of good prognosis for TTR (P = 0.001) and DSS (P < 0.001). This effect was particularly evident in the group of patients receiving chemo-endocrine therapy (TTR (P = 0.015) and DSS (P < 0.001)). Cox models confirmed AR as an independent variable for both TTR (P = 0.003, HR 0.444, 95%CI 0.258–0.765) and DSS (P < 0.001, HR 0.135, 95%CI 0.054–0.337). Thus, we focused on ER-positive luminal B breast cancer that may be selected for chemotherapy because of their more aggressive immunophenotype. In this subset AR expression identified a group of patients with better prognosis for TTR (P = 0.017, HR 0.521, 95%CI 0.306–0.888) and DSS (P = 0.001, HR 0.276, 95% CI 0.130–0.588). AR expression is an independent prognostic factor of better outcome in patients with ER-positive breast cancers.

Keywords

Androgen receptor Prognosis Estrogen receptor Breast cancer Chemotherapy 

Notes

Acknowledgments

This study was funded by Compagnia San Paolo di Torino, Cassa di Risparmio di Torino, AIRC 2007–2009, Ricerca Finalizzata Regione Piemonte 2008, MIUR-PRIN 2008.

Supplementary material

10549_2010_761_MOESM1_ESM.pdf (78 kb)
Supplementary material 1 (PDF 79 kb)

References

  1. 1.
    Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32CrossRefPubMedGoogle Scholar
  2. 2.
    Schippinger W, Regitnig P, Dandachi N et al (2006) Evaluation of the prognostic significance of androgen receptor expression in metastatic breast cancer. Virchows Arch 449:24–30CrossRefPubMedGoogle Scholar
  3. 3.
    Peters AA, Buchanan G, Ricciardelli C et al (2009) Androgen receptor inhibits estrogen receptor-alfa activity and is prognostic in breast cancer. Cancer Res 69:6131–6140CrossRefPubMedGoogle Scholar
  4. 4.
    Moinfar F, Okcu M, Tsybrovskyy O et al (2003) Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 98:703–711CrossRefPubMedGoogle Scholar
  5. 5.
    Kuenen-Boumeester V, Van der Kwast TH, Claassen CC et al (1996) The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 32A:1560–1565CrossRefPubMedGoogle Scholar
  6. 6.
    Sapino A, Righi L, Cassoni P et al (2001) Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. Mod Pathol 14:768–776CrossRefPubMedGoogle Scholar
  7. 7.
    Kollara A, Kahn HJ, Marks A et al (2001) Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers. Breast Cancer Res Treat 67:245–253CrossRefPubMedGoogle Scholar
  8. 8.
    Ogawa Y, Hai E, Matsumoto K et al (2008) Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 13:431–435CrossRefPubMedGoogle Scholar
  9. 9.
    Gatalica Z (1997) Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract 193:753–758PubMedGoogle Scholar
  10. 10.
    Niemeier LA, Dabbs DJ, Beriwal S et al (2009) Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. doi: 10.1038/modpathol.2009.159
  11. 11.
    Bryan RM, Mercer RJ, Bennett RC et al (1984) Androgen receptors in breast cancer. Cancer 54:2436–2440CrossRefPubMedGoogle Scholar
  12. 12.
    Agrawal AK, Jeleń M, Grzebieniak Z et al (2008) Androgen receptors as a prognostic and predictive factor in breast cancer. Folia Histochem Cytobiol 46:269–276CrossRefPubMedGoogle Scholar
  13. 13.
    Gonzalez-Angulo AM, Stemke-Hale K, Palla SL et al (2009) Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 15:2472–2478CrossRefPubMedGoogle Scholar
  14. 14.
    Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874CrossRefPubMedGoogle Scholar
  15. 15.
    Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752CrossRefPubMedGoogle Scholar
  16. 16.
    Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423CrossRefPubMedGoogle Scholar
  17. 17.
    Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750CrossRefPubMedGoogle Scholar
  18. 18.
    Sapino A, Marchiò C, Senetta R et al (2006) Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch 449:288–296CrossRefPubMedGoogle Scholar
  19. 19.
    Marchiò C, Lambros MB, Gugliotta P et al (2009) Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol 219:16–24CrossRefPubMedGoogle Scholar
  20. 20.
    Liu S, Chia SK, Mehl E et al (2010) Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 119:53–61CrossRefPubMedGoogle Scholar
  21. 21.
    Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145CrossRefPubMedGoogle Scholar
  22. 22.
    McShane LM, Altman DG, Sauerbrei W et al (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res treat 100:229–235CrossRefPubMedGoogle Scholar
  23. 23.
    Park S, Koo J, Park HS et al (2009) Expression of androgen receptors in primary breast cancer. Ann Oncol. doi: 10.1093/annonc/mdp510
  24. 24.
    Koo JS, Jung W, Jeong J (2009) The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast cancer. Jpn J Clin Oncol 39:560–568CrossRefPubMedGoogle Scholar
  25. 25.
    De Amicis F, Thrugnansampanthan J, Cui Y et al (2009) Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. doi: 10.1007/s10549-009-0436-8
  26. 26.
    Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 20:1319–1329CrossRefPubMedGoogle Scholar
  27. 27.
    Hess-Wilson JK, Daly HK, Zagorski WA et al (2006) Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. Cancer Res 66:11998–12008CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Isabella Castellano
    • 1
  • Elena Allia
    • 1
  • Valeria Accortanzo
    • 2
  • Anna Maria Vandone
    • 3
  • Luigi Chiusa
    • 1
  • Riccardo Arisio
    • 4
  • Antonio Durando
    • 2
  • Michela Donadio
    • 3
  • Gianni Bussolati
    • 1
  • Alan S. Coates
    • 5
    • 6
  • Giuseppe Viale
    • 7
  • Anna Sapino
    • 1
  1. 1.Department of Biomedical Sciences and Human OncologyUniversity of TurinTurinItaly
  2. 2.Department of Obstetrics and GynaecologySant’Anna HospitalTurinItaly
  3. 3.Centro Oncologico Subalpino (COES), Molinette HospitalTurinItaly
  4. 4.Department of PathologySant’Anna HospitalTurinItaly
  5. 5.International Breast Cancer Study GroupBernSwitzerland
  6. 6.School of Public HealthUniversity of SydneySydneyAustralia
  7. 7.Division of Pathology and Laboratory MedicineEuropean Institute of Oncology, University of MilanMilanItaly

Personalised recommendations